K-CAB FILM-COATED TABLETS 50MG [SIN16672P]

Product Info

K-CAB FILM-COATED TABLETS 50MG

[SIN16672P]

INDICATIONS
K-CAB is indicated for the treatment of Erosive Gastroesophageal Reflux Diseases, Non-Erosive Gastroesophageal Reflux Disease and Gastric Ulcer. K-CAB is also indicated for the eradication of H. pylori when concurrently given with appropriate antibiotic therapy treatment in patients with peptic ulcer and/or chronic atrophic gastritis.

DOSAGE AND MODE OF ADMINISTRATION
For Adult Population:

• Treatment of Erosive Gastroesophageal Reflux Disease:
  50 mg once daily for 4 weeks. For patients who do not heal or have persistent symptoms after 4 weeks, an additional 4-week treatment may be considered.

• Treatment of Non-Erosive Gastroesophageal Reflux Disease:
  50 mg once daily for 4 weeks.

• Treatment of Gastric Ulcer:
  50 mg once daily for 8 weeks.

• Eradication of H. pylori concurrently given with appropriate antibiotic therapy treatment in patients with peptic ulcer and/or chronic atrophic gastritis:
  Patients with H. pylori infection should be treated with eradication therapy. Tegoprazan 50 mg, clarithromycin 500 mg, and amoxicillin 1 g are orally administered twice daily for 7 days.
  When selecting appropriate combination therapy, consideration should be given to official national, regional and local guidance regarding bacterial resistance, duration of treatment and appropriate use of antibacterial agents.

K-CAB can be taken orally without regard to food.

For Pediatric Population:

Clinical safety and efficacy of K-CAB in Pediatric and adolescent patients have not been established.

CONTRAINDICATIONS
Patients with hypersensitivity to the tegoprazan, any of the product components or substituted benzimidazoles. Patients who take atazanavir, nelfinavir or rilpivirine-containing products. Pregnant women or nursing mothers.